<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2020.95028</article-id><article-id pub-id-type="publisher-id">PI-37916</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20200500000_81702877.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  岩陀治疗慢性支气管炎作用机制的网络药理学研究
  Study on the Mechanism of Treatment of Chronic Bronchitis of 
  Rodgersia sambucifolia Hemsl. Based on Network Pharmacology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>小芬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>旭龙</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>方</surname><given-names>镕泽</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>华</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>祥培</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>成都中医药大学，药学院，四川 成都</addr-line></aff><aff id="aff3"><addr-line>贵州中医药大学，药学院，贵州 贵阳</addr-line></aff><aff id="aff4"><addr-line>遵义食品药品检验所，贵州 遵义</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>08</month><year>2020</year></pub-date><volume>09</volume><issue>05</issue><fpage>186</fpage><lpage>195</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：采用网络药理学的方法探讨岩陀治疗慢性支气管炎的分子作用机制。方法：通过中药系统药理学分析平台(TCMSP)等数据库查找岩陀的有效成分；利用Swiss Target Prediction服务器反向药效团匹配等数据库预测有效成分的作用靶点；运用Gene Cards等数据库查找慢性支气管炎相关的靶点。采用cytoscape3.6.1软件构建“有效成分–潜在靶点–疾病”网络，并进行可视化分析；同时利用DAVID 6.7进行GO和KEGG富集分析。结果：得到9个岩陀的有效成分，27个潜在靶点，其中细胞肿瘤抗原p53、血管内皮生长因子A、甘油醛-3-磷酸脱氢酶、IL10等靶点可能是岩陀治疗慢性支气管炎的潜在靶点。岩陀治疗慢性支气管炎主要涉及蛋白质磷酸化、细胞凋亡过程、细胞增殖、炎症反应、免疫反应等生物过程，通过调控前列腺癌、TNF、非小细胞肺、PI3K-Akt、HIF-1、T细胞受体等信号通路来治疗慢性支气管炎。结论：本研究初步揭示了岩陀治疗慢性支气管炎的分子作用机制，为进一步的药效物质基础及作用机制的实验研究奠定了基础。 Objective: To explore the possible molecular mechanism of the treatment of chronic bronchitis by Rodgersia sambucifolia Hemsl. based on network pharmacology. Methods: Search the Chinese medicine system pharmacology analysis platform (TCMSP) and other databases to screen the active components of the radish; use the Swiss Target Prediction server reverse pharmacophore matching database to predict the target of the active ingredients; use Gene Cards and other databases to predict chronic bronchitis Disease target. The cytoscape 3.6.1 software was used to construct an “active ingredient-potential target-disease” network for visual analysis. The DAVID 6.7 online tool was used to perform gene ontology (GO) analysis of potential genes and the Kyoto Gene and Genomic Encyclopedia (KEGG) pathway enrichment analysis. Results: There are 9 active ingredients in the treatment of chronic bronchitis, and there are 27 potential targets, including cell tumor antigen p53, vascular endothelial growth factor A, glyceraldehyde-3-phosphate dehydrogenase, RAC-α serine/su Targets such as protein kinases, IL10, and IL6 which may be important targets for the treatment of chronic bronchitis. Rodgersia sambucifolia Hemsl. treatment of chronic bronchitis mainly involves protein phosphorylation, apoptosis process, biosynthesis process, cell proliferation, cell-to-drug response, inflammatory reaction, immune response and other biological processes, through regulation of hepatitis B, proteoglycan, prostate cancer, TNF, Erb, non-small cell lung, PI3K-Akt, MAPK, HIF-1, T cell receptor and other signaling pathways to treat chronic bronchitis. Conclusion: This study preliminarily revealed the molecular mechanism of action of Rodgersia sambucifolia Hemsl. in the treatment of chronic bronchitis, laying a foundation for further experimental research on the basis and mechanism of pharmacodynamics. 
  
 
</p></abstract><kwd-group><kwd>岩陀，有效成分，慢性支气管炎，网络药理学，分子机制, Rodgersia sambucifolia Hemsl.</kwd><kwd> Active Ingredient</kwd><kwd> Chronic Bronchitis</kwd><kwd> Network Pharmacology</kwd><kwd> Molecular Mechanism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：采用网络药理学的方法探讨岩陀治疗慢性支气管炎的分子作用机制。方法：通过中药系统药理学分析平台(TCMSP)等数据库查找岩陀的有效成分；利用Swiss Target Prediction服务器反向药效团匹配等数据库预测有效成分的作用靶点；运用Gene Cards等数据库查找慢性支气管炎相关的靶点。采用cytoscape3.6.1软件构建“有效成分–潜在靶点–疾病”网络，并进行可视化分析；同时利用DAVID 6.7进行GO和KEGG富集分析。结果：得到9个岩陀的有效成分，27个潜在靶点，其中细胞肿瘤抗原p53、血管内皮生长因子A、甘油醛-3-磷酸脱氢酶、IL10等靶点可能是岩陀治疗慢性支气管炎的潜在靶点。岩陀治疗慢性支气管炎主要涉及蛋白质磷酸化、细胞凋亡过程、细胞增殖、炎症反应、免疫反应等生物过程，通过调控前列腺癌、TNF、非小细胞肺、PI3K-Akt、HIF-1、T细胞受体等信号通路来治疗慢性支气管炎。结论：本研究初步揭示了岩陀治疗慢性支气管炎的分子作用机制，为进一步的药效物质基础及作用机制的实验研究奠定了基础。</p></sec><sec id="s2"><title>关键词</title><p>岩陀，有效成分，慢性支气管炎，网络药理学，分子机制</p></sec><sec id="s3"><title>Study on the Mechanism of Treatment of Chronic Bronchitis of Rodgersia sambucifolia Hemsl. Based on Network Pharmacology</title><p>Xiaofen Li<sup>1</sup>, Xulong Huang<sup>2</sup>, Rongze Fang<sup>2</sup>, Hua Feng<sup>3</sup>, Xiangpei Wang<sup>2*</sup></p><p><sup>1</sup>School of Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan</p><p><sup>2</sup>School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou</p><p><sup>3</sup>Zunyi Food and Drug Inspection Institute, Zunyi Guizhou</p><p><img src="//html.hanspub.org/file/5-1710233x5_hanspub.png" /></p><p>Received: Sep. 9<sup>th</sup>, 2020; accepted: Sep. 21<sup>st</sup>, 2020; published: Sep. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/5-1710233x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the possible molecular mechanism of the treatment of chronic bronchitis by Rodgersia sambucifolia Hemsl. based on network pharmacology. Methods: Search the Chinese medicine system pharmacology analysis platform (TCMSP) and other databases to screen the active components of the radish; use the Swiss Target Prediction server reverse pharmacophore matching database to predict the target of the active ingredients; use Gene Cards and other databases to predict chronic bronchitis Disease target. The cytoscape 3.6.1 software was used to construct an “active ingredient-potential target-disease” network for visual analysis. The DAVID 6.7 online tool was used to perform gene ontology (GO) analysis of potential genes and the Kyoto Gene and Genomic Encyclopedia (KEGG) pathway enrichment analysis. Results: There are 9 active ingredients in the treatment of chronic bronchitis, and there are 27 potential targets, including cell tumor antigen p53, vascular endothelial growth factor A, glyceraldehyde-3-phosphate dehydrogenase, RAC-α serine/su Targets such as protein kinases, IL10, and IL6 which may be important targets for the treatment of chronic bronchitis. Rodgersia sambucifolia Hemsl. treatment of chronic bronchitis mainly involves protein phosphorylation, apoptosis process, biosynthesis process, cell proliferation, cell-to-drug response, inflammatory reaction, immune response and other biological processes, through regulation of hepatitis B, proteoglycan, prostate cancer, TNF, Erb, non-small cell lung, PI3K-Akt, MAPK, HIF-1, T cell receptor and other signaling pathways to treat chronic bronchitis. Conclusion: This study preliminarily revealed the molecular mechanism of action of Rodgersia sambucifolia Hemsl. in the treatment of chronic bronchitis, laying a foundation for further experimental research on the basis and mechanism of pharmacodynamics.</p><p>Keywords:Rodgersia sambucifolia Hemsl., Active Ingredient, Chronic Bronchitis, Network Pharmacology, Molecular Mechanism</p><disp-formula id="hanspub.37916-formula30"><graphic xlink:href="//html.hanspub.org/file/5-1710233x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1710233x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-1710233x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>慢性支气管炎是气管及其周围组织产生的一种非特异性炎症反应，主要表现咳嗽、咳痰，最终导致循环系统衰竭。随着支气管炎患病率的提高，其死亡率也明显增加。感染是慢性支气管炎加剧的原因之一，而炎症反应才是慢性支气管炎发生发展的核心机制 [<xref ref-type="bibr" rid="hanspub.37916-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref2">2</xref>]。因此，目前对慢性支气管炎的治疗以抗生素为主，但长期、频繁使用抗生素会增加细菌耐药性和药物不良反应的发生 [<xref ref-type="bibr" rid="hanspub.37916-ref3">3</xref>]，使其治疗难度显著增加。当前研究表明中医药在慢性支气管炎治疗上具有很大的优势，日益受到了广泛的重视 [<xref ref-type="bibr" rid="hanspub.37916-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref5">5</xref>]。</p><p>岩陀为虎耳草科鬼灯檠属植物西南鬼灯檠Rodgersia sambucifolia Hemsl.，具有清热凉血、调经止痛之功效，临床主要用于治疗肠炎、痢疾、痛经、风湿性关节炎等 [<xref ref-type="bibr" rid="hanspub.37916-ref6">6</xref>]。岩陀中所含的岩白菜素、齐墩果酸及槲皮素等黄酮类和萜类成分为其有效成分，其中岩白菜素被《中华人民共和国药典》作为镇咳祛痰药，主要用于治疗慢性支气管炎、胃溃疡、十二指肠溃疡，且其疗效显著 [<xref ref-type="bibr" rid="hanspub.37916-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref11">11</xref>]。然而，目前缺乏分子层面阐释岩陀治疗慢性支气管炎的分子机研究，亟待进一步加强。网络药理学整体性、系统性的特点与中药“多成分、多途径、多靶点”协同作用的特点不谋而合，为中医药复杂系统的作用机制的研究提供了新的视角和思路 [<xref ref-type="bibr" rid="hanspub.37916-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref15">15</xref>]。基于此，本文采用网络药理学的方法，通过预测岩陀有效成分的作用靶点及信号通路，以期为岩陀治疗慢性支气管炎的分子机制和深入研究提供参考依据。</p></sec><sec id="s6"><title>2. 方法</title><sec id="s6_1"><title>2.1. 岩陀化学成分的建立</title><p>以岩陀为关键词，通过查阅《中药大辞典》、《中华本草》、中国知网(CNKI, http://kns.cnki.net/kns/brief/default_result.aspx)、PubMed数据库(https://www.ncbi.nlm.nih.gov/)和中药系统药理学分析平台(TCMSP, http://tcmspw.com/tsms)，搜索岩陀报道的全部化学成分。</p></sec><sec id="s6_2"><title>2.2. 有效成分的筛选</title><p>口服生物利用度(Oral bioavailability, OB)是评估药物能否开发的关键参数，也是评价中药临床疗效的有效指标。类药性(Drug likeness, DL)目前被广泛用于评价先导化合物药物是否有可能成药的重要依据。在TCMSP数据库中认为OB ≥ 30%的分子具有较好的口服生物利用度，DL ≥ 0.18的分子具有较好的类药性 [<xref ref-type="bibr" rid="hanspub.37916-ref16">16</xref>]。以上述标准或生物活性(文献已有报道)为标准 [<xref ref-type="bibr" rid="hanspub.37916-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref17">17</xref>]，筛选岩陀的有效成分。</p></sec><sec id="s6_3"><title>2.3. 药物靶点与疾病靶点的建立</title><p>通过TCMSP数据库和Swiss Target Prediction (http://www.swisstargetprediction.ch/)数据库，检索岩陀有效成分对应的靶点，建立成分靶点数据集。通过Gene Cards数据库(https://www.genecards.org/)检索慢性支气管炎相关的靶点，建立疾病靶点数据集。</p></sec><sec id="s6_4"><title>2.4. 潜在靶点的筛选及网络的构建</title><p>将药物靶点与疾病靶点进行取交集，存在交集中的靶点即为岩陀治疗慢性支气管炎的预测靶点。将其导入String数据库(https://string-db.org/)中构建“药物–疾病”交集靶点PPI网络，并采用cytoscape 3.6.1软件对PPI网络进行可视化分析，以网络中每个节点的拓扑参数“节点连接度”(Degree)、“节点介度”(Betweenness centrality)、“节点紧密度”(Closeness centrality)的中位数为卡值，选取同时满足大于“节点介度”、“节点紧密度”和2倍“节点连接度”的节点，作为潜在靶点；同时采用cytoscape3.6.1软件构建“中药-活性成分-核心靶点-疾病”网络。</p></sec><sec id="s6_5"><title>2.5. 生物过程分析</title><p>将潜在靶点导入DAVID (https://david.ncifcrf.gov/)数据库中进行基因本体(GO)生物学过程和基于京都基因与基因组百科全书(KEGG)通路富集分析，以P ≤ 0.01作为筛选标准，筛选出具有极显著性差异的生物过程和信号通路。</p></sec><sec id="s6_6"><title>2.6. 构建岩陀治疗慢性支气管炎的通路标注图</title><p>运用KEGG (https://www.genome.jp/kegg/)数据库中的KEGG Mapper功能，将潜在靶点映射在相关信号通路上，揭示岩陀治多靶点、多途径的治疗作用。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 岩陀有效成分的筛选</title><p>通过《中华本草》、中国知网、PubMed、TCMSP等数据库共得到岩陀治已报道的47个化学成分，根据ADME参数(OB ≥ 30%和DL ≥ 0.18)或生物活性(文献已有报道)为标准，共筛选得到9个有效成分，结果见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Related parameters of effective components of Rodgersia sambucifolia Hems</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Mol ID</th><th align="center" valign="middle" >成分</th><th align="center" valign="middle" >英文名</th><th align="center" valign="middle" >靶点数</th><th align="center" valign="middle" >OB (%)</th><th align="center" valign="middle" >DL</th></tr></thead><tr><td align="center" valign="middle" >MOL002816</td><td align="center" valign="middle" >岩白菜素</td><td align="center" valign="middle" >Bergenin</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >14.11</td><td align="center" valign="middle" >0.34</td></tr><tr><td align="center" valign="middle" >MOL000098</td><td align="center" valign="middle" >槲皮素</td><td align="center" valign="middle" >quercetin</td><td align="center" valign="middle" >205</td><td align="center" valign="middle" >46.43</td><td align="center" valign="middle" >0.28</td></tr><tr><td align="center" valign="middle" >MOL002815</td><td align="center" valign="middle" >熊果苷</td><td align="center" valign="middle" >Arbutin</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >6.82</td><td align="center" valign="middle" >0.15</td></tr><tr><td align="center" valign="middle" >MOL000298</td><td align="center" valign="middle" >麦角甾醇</td><td align="center" valign="middle" >ergosterol</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >14.29</td><td align="center" valign="middle" >0.72</td></tr><tr><td align="center" valign="middle" >MOL000513</td><td align="center" valign="middle" >没食子酸</td><td align="center" valign="middle" >Gallic acid</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >31.69</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >MOL000263</td><td align="center" valign="middle" >齐墩果酸</td><td align="center" valign="middle" >oleanolic acid</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >29.02</td><td align="center" valign="middle" >0.76</td></tr><tr><td align="center" valign="middle" >MOL001807</td><td align="center" valign="middle" >紫丁香酸</td><td align="center" valign="middle" >Cedar acid</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >47.78</td><td align="center" valign="middle" >0.06</td></tr><tr><td align="center" valign="middle" >MOL000492</td><td align="center" valign="middle" >(+)-儿茶素</td><td align="center" valign="middle" >(+)-catechin</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >2.06</td><td align="center" valign="middle" >0.7</td></tr><tr><td align="center" valign="middle" >MOL000359</td><td align="center" valign="middle" >β-谷甾醇</td><td align="center" valign="middle" >β-sitosterol</td><td align="center" valign="middle" >103</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr></tbody></table></table-wrap><p>表1. 岩陀有效成分的相关参数</p></sec><sec id="s7_2"><title>3.2. 岩陀有效成分的靶点预测</title><p>将TCMSP、Swiss Target Prediction数据库检索得到的所有靶点，删除重复靶点，最终得到9个有效成分对应的靶点，共计422个靶点，结果见表1。通过Gene Cards数据库共检索整合得到962个疾病靶点。</p></sec><sec id="s7_3"><title>3.3. 岩陀治疗慢性支气管炎潜在靶点的筛选</title><p>将药物靶点与疾病靶点进行取交集，得到151个交集靶点，并绘制韦恩图，结果见图1。利用String数据库(https://string-db.org/)构建PPI网络，并采用cytoscape 3.6.1软件对PPI网络进行可视化分析，得到所有节点三个拓扑参数的中位数值分别为34 (Degree)、0.0016 (Betweenness centrality)、0.5556 (Closeness centrality)，选取满足筛选标准的节点，作为潜在靶点，结果见表2；同时采用cytoscape3.6.1软件构建“潜在靶点”PPI网络，结果见图2。</p><p>图1. 岩陀治疗慢性支气管炎交集靶点韦恩图</p><p>图2. 岩陀治疗慢性支气管炎交集靶点蛋白互作网络(节点的大小和不同颜色代表Degree值的大小，节点越大Degree 值越大，Degree值越大表明靶点越相关)</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Related topological parameters of the potential targets of Rodgersia sambucifolia Hemsl. in the treatment of chronic bronchiti</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >UniProt CID</th><th align="center" valign="middle" >Gene name</th><th align="center" valign="middle" >Protein name</th><th align="center" valign="middle" >Degree</th><th align="center" valign="middle" >Closeness Centrality</th><th align="center" valign="middle" >Betweenness Centrality</th></tr></thead><tr><td align="center" valign="middle" >P24385</td><td align="center" valign="middle" >CCND1</td><td align="center" valign="middle" >G1/S-specific cyclin-D1</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >0.6881</td><td align="center" valign="middle" >0.0100</td></tr><tr><td align="center" valign="middle" >P31749</td><td align="center" valign="middle" >AKT1</td><td align="center" valign="middle" >RAC-alpha serine/threonine-protein kinase</td><td align="center" valign="middle" >106</td><td align="center" valign="middle" >0.7732</td><td align="center" valign="middle" >0.0290</td></tr><tr><td align="center" valign="middle" >Q07817</td><td align="center" valign="middle" >BCL2L1</td><td align="center" valign="middle" >Bcl-2-like protein 1</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >0.6466</td><td align="center" valign="middle" >0.0060</td></tr><tr><td align="center" valign="middle" >P04637</td><td align="center" valign="middle" >TP53</td><td align="center" valign="middle" >Cellular tumor antigen p53</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >0.8197</td><td align="center" valign="middle" >0.0500</td></tr><tr><td align="center" valign="middle" >P00533</td><td align="center" valign="middle" >EGFR</td><td align="center" valign="middle" >Epidermal growth factor receptor</td><td align="center" valign="middle" >98</td><td align="center" valign="middle" >0.7426</td><td align="center" valign="middle" >0.0339</td></tr><tr><td align="center" valign="middle" >P01133</td><td align="center" valign="middle" >EGF</td><td align="center" valign="middle" >Pro-epidermal growth factor</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >0.7246</td><td align="center" valign="middle" >0.0169</td></tr><tr><td align="center" valign="middle" >P01112</td><td align="center" valign="middle" >HRAS</td><td align="center" valign="middle" >GTPase HRas</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >0.6726</td><td align="center" valign="middle" >0.0108</td></tr><tr><td align="center" valign="middle" >P15692</td><td align="center" valign="middle" >VEGFA</td><td align="center" valign="middle" >Vascular endothelial growth factor A</td><td align="center" valign="middle" >109</td><td align="center" valign="middle" >0.7853</td><td align="center" valign="middle" >0.0378</td></tr><tr><td align="center" valign="middle" >P42574</td><td align="center" valign="middle" >CASP3</td><td align="center" valign="middle" >Caspase-3</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >0.7500</td><td align="center" valign="middle" >0.0236</td></tr><tr><td align="center" valign="middle" >P07900</td><td align="center" valign="middle" >HSP90AA1</td><td align="center" valign="middle" >Heat shock protein HSP 90-alpha</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >0.6849</td><td align="center" valign="middle" >0.0186</td></tr><tr><td align="center" valign="middle" >P22301</td><td align="center" valign="middle" >IL10</td><td align="center" valign="middle" >Interleukin-10</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >0.6696</td><td align="center" valign="middle" >0.0100</td></tr><tr><td align="center" valign="middle" >P05231</td><td align="center" valign="middle" >IL6</td><td align="center" valign="middle" >Interleukin-6</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >0.7653</td><td align="center" valign="middle" >0.0385</td></tr><tr><td align="center" valign="middle" >P01375</td><td align="center" valign="middle" >TNF</td><td align="center" valign="middle" >Tumor necrosis factor</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >0.7500</td><td align="center" valign="middle" >0.0307</td></tr><tr><td align="center" valign="middle" >P60484</td><td align="center" valign="middle" >PTEN</td><td align="center" valign="middle" >Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >0.6608</td><td align="center" valign="middle" >0.0081</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >P01584</th><th align="center" valign="middle" >IL1B</th><th align="center" valign="middle" >Interleukin-1 beta</th><th align="center" valign="middle" >72</th><th align="center" valign="middle" >0.6550</th><th align="center" valign="middle" >0.0088</th></tr></thead><tr><td align="center" valign="middle" >P04626</td><td align="center" valign="middle" >ERBB2</td><td align="center" valign="middle" >Receptor tyrosine-protein kinase erbB-2</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >0.6550</td><td align="center" valign="middle" >0.0077</td></tr><tr><td align="center" valign="middle" >P05412</td><td align="center" valign="middle" >JUN</td><td align="center" valign="middle" >Transcription factor AP-1</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >0.7143</td><td align="center" valign="middle" >0.0141</td></tr><tr><td align="center" valign="middle" >P28482</td><td align="center" valign="middle" >MAPK1</td><td align="center" valign="middle" >Mitogen-activated protein kinase 1</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >0.7075</td><td align="center" valign="middle" >0.0213</td></tr><tr><td align="center" valign="middle" >P01106</td><td align="center" valign="middle" >MYC</td><td align="center" valign="middle" >Myc proto-oncogene protein</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >0.7317</td><td align="center" valign="middle" >0.0184</td></tr><tr><td align="center" valign="middle" >P13500</td><td align="center" valign="middle" >CCL2</td><td align="center" valign="middle" >C-C motif chemokine 2</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >0.6494</td><td align="center" valign="middle" >0.0070</td></tr><tr><td align="center" valign="middle" >P27361</td><td align="center" valign="middle" >MAPK3</td><td align="center" valign="middle" >Mitogen-activated protein kinase 3</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >0.7177</td><td align="center" valign="middle" >0.0146</td></tr><tr><td align="center" valign="middle" >P12931</td><td align="center" valign="middle" >SRC</td><td align="center" valign="middle" >Proto-oncogene tyrosine-protein kinase Src</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >0.6977</td><td align="center" valign="middle" >0.0194</td></tr><tr><td align="center" valign="middle" >P14780</td><td align="center" valign="middle" >MMP9</td><td align="center" valign="middle" >Matrix metalloproteinase-9</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >0.7042</td><td align="center" valign="middle" >0.0141</td></tr><tr><td align="center" valign="middle" >P08253</td><td align="center" valign="middle" >MMP2</td><td align="center" valign="middle" >72 kDa type IV collagenase</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >0.6466</td><td align="center" valign="middle" >0.0057</td></tr><tr><td align="center" valign="middle" >P35354</td><td align="center" valign="middle" >PTGS2</td><td align="center" valign="middle" >Prostaglandin G/H synthase 2</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >0.7042</td><td align="center" valign="middle" >0.0242</td></tr><tr><td align="center" valign="middle" >P04406</td><td align="center" valign="middle" >GAPDH</td><td align="center" valign="middle" >Glyceraldehyde-3-phosphate dehydrogenase</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >0.8197</td><td align="center" valign="middle" >0.0512</td></tr><tr><td align="center" valign="middle" >P08253</td><td align="center" valign="middle" >MMP2</td><td align="center" valign="middle" >72 kDa type IV collagenase</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >0.6466</td><td align="center" valign="middle" >0.0057</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 岩陀治疗慢性支气管炎潜在靶点的相关拓扑参数</p></sec><sec id="s7_4"><title>3.4. 岩陀治疗慢性支气管炎潜在靶点网络构建</title><p>通过cytoscape3.6.1软件分别构建“岩陀–有效成分”网络、“有效成分–靶点”网络、“疾病–靶点”网络，将以上网络合并成为一个网络，最终构建“岩陀–有效成分–核心靶点–疾病”网络，结果见图3。</p><p>图3. 岩陀治疗慢性支气管炎“中药–有效成分–核心靶点–疾病”网络</p></sec><sec id="s7_5"><title>3.5. GO生物过程富集分析</title><p>将27个潜在靶点导入DAVID数据库进行GO生物过程富集分析，保留P ≤ 0.01的结果。结果共富集得到76生物过程(Biological process, BP)、12分子功能(Molecular function, MF)和10细胞组分(Cellular component, CC)。根据P-value越小，显著性越高的原则，列举了排名前20的生物过程，结果见图4。结果表明岩陀治疗慢性支气管炎主要涉及的生物过程包括蛋白质磷酸化的正调控，一氧化氮生物合成过程的正调控，MAPK级联，平滑肌细胞增殖的正调控，脂多糖介导的信号通路，蛋白激酶B信号传导，对糖皮质激素的反应等。岩陀治疗慢性支气管炎可能是通过调控这些生物过程起到治疗作用。</p><p>图4. 岩陀治疗慢性支气管炎排名前20的生物过程富集结果(不同颜色代表不同的生物过程)</p><p>图5. 岩陀治疗慢性支气管炎“靶点–通路”网络(节点越大代表信号通路作用越重要，红色边代表不同靶点的相互作用，绿色边代表不同信号通路与靶点之间的相互作用)</p></sec><sec id="s7_6"><title>3.6. KEGG通路富集分析</title><p>将27个潜在靶点导入DAVID数据库进行KEGG通路富集分析，保留P ≤ 0.01的结果，使用Cytoscape3.6.1软件进行可视化分析，构建“靶点-通路”网络，结果见图5。根据P-value越小，显著性越高的原则，列举了排名前20的信号通路，结果见图6。结果共富集得到85条信号通路，其中主要的信号通路包括前列腺癌，胰腺癌，TNF信号通路，非小细胞肺癌，PI3K-Akt信号通路，雌激素，MAPK信号通路，HIF-1信号通路，慢性粒细胞白血病，NOD样受体信号通路等，提示岩陀治疗慢性支气管炎可能是以上多条信号通路共同参与的结果。</p><p>图6. 岩陀治疗慢性支气管炎排名前20的KEGG通路富集结果(不同颜色代表不同的生物过程)</p></sec><sec id="s7_7"><title>3.7. 岩陀治疗慢性支气管炎的通路注释图</title><p>将27个潜在靶点输入KEGG数据库的KEGG Mapper功能中，标注出潜在靶点在每条相关信号通路中所占的个数。结果显示有11个靶蛋白参与MAPK信号通路的相关调控，提示岩陀治疗慢性支气管炎与多个靶点、多条途径相关联，结果见图7。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>慢性支气管炎是一种慢性非特异性炎症，临床主要特征为咳嗽及反复发作，是一种严重危害人体身体健康的慢性多发病。近些年，随着环境的恶化，慢性支气管炎发病率急剧上升。中医将其归属于“喘证”、“痰饮”、“咳嗽”等范畴，其发病的本质是脾肾亏虚、肾不纳气。针对其慢性、反复发作的特点，中医药显示出其独特的优势。岩陀为白族、傈族习用的民族药，民间广泛应用治疗慢性支气管炎，且疗效显著。因此，揭示岩陀治疗慢性支气管炎的分子机制有利于促进民族药的深入发展。</p><p>本研究采用网络药理学的方法，寻找到了岩陀9个有效成分，主要为黄酮类、萜类以及甾醇类成分。结果发现岩白菜素为岩陀治止咳、抗菌和消炎的主要成分 [<xref ref-type="bibr" rid="hanspub.37916-ref7">7</xref>]。槲皮素可通过减轻炎症细胞的浸润达到抑制大鼠气管收缩的作用 [<xref ref-type="bibr" rid="hanspub.37916-ref18">18</xref>]。任晓磊 [<xref ref-type="bibr" rid="hanspub.37916-ref19">19</xref>] 等基于代谢组学，发现岩白菜素可通过调节支链氨基酸代谢过程以及甘氨酸和苏氨酸的代谢来治疗慢性支气管炎。紫花高乌头总生物碱可降低慢性支气管炎大鼠血清</p><p>图7. 岩陀治疗慢性支气管炎潜在靶点在MAPK信号通路上的注释图(红色标注的基因代表潜在靶点，绿色标注的基因代表通路原有靶点)</p><p>IL-1、IL-8和TNF-α水平，其机制可能与平衡细胞因子生有关 [<xref ref-type="bibr" rid="hanspub.37916-ref20">20</xref>]。秘精益气法通过调节慢性支气管炎大鼠肺组织IL-4、IL-10的水平，抑制炎症因子的释放，增强抗炎细胞因子活性，调节促炎、抗炎细胞因子间的失衡状态，从而对慢性支气管炎大鼠产生治疗作用 [<xref ref-type="bibr" rid="hanspub.37916-ref21">21</xref>]。</p><p>通过GO生物过程富集分析，结果表明岩陀治疗慢性支气管炎主要涉及的生物过程有一氧化氮生物合成过程，MAPK级联，脂多糖介导的信号通路等。一氧化氮合酶(NOS)主要存在于血管内皮细胞、气道及肺泡上皮细胞以及某些炎症细胞中，可生NO，致使炎症因子释放增加，进而加重了病程 [<xref ref-type="bibr" rid="hanspub.37916-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.37916-ref22">22</xref>]。脂多糖是一种内毒素，其作用是通过存在于宿主细胞的细胞膜表面的Toll样受体(TLR4)而体现的，最终可引起相似于慢性支气管炎的气道病变 [<xref ref-type="bibr" rid="hanspub.37916-ref23">23</xref>]。KEGG通路富集分析，结果表明岩陀主要是通过调控前列腺癌、胰腺癌、TNF信号通路、PI3K-Akt信号通路、MAPK信号通路、NOD样受体信号通路发挥治疗慢性支气管炎。目前，研究发现炎症反应是慢性支气管炎发展的主要机制，其中心环节为氧化应激，最终导致肺气肿、呼吸功能衰竭等 [<xref ref-type="bibr" rid="hanspub.37916-ref2">2</xref>]。在炎症反应过程中，前列腺素的上调可介导炎性细胞的迁移、凋亡、增生、血管张力及下游细胞因子的产生，促进了炎症的发展 [<xref ref-type="bibr" rid="hanspub.37916-ref24">24</xref>]。MAPK是细胞内一类高度保守的丝氨酸/苏氨酸蛋白激酶，参与细胞内多种生物学反应包括细胞转化、凋亡、应激调控等，而其与炎症反应的发生发展密不可分。</p><p>综上所述，本研究通过蛋白相互作分析，发现这些靶点蛋白互相关联、彼此相互调节。通过构建网络图，发现岩陀治疗慢性支气管炎的机制涉及多种生物过程、多条通路，体现了中药(民族药)多成分–多靶点–多途径的作用特点。提示岩陀治疗慢性支气管炎的机制可能是多靶点、多条信号通路共同作用的结果。但是具体的结果仍需要进一步的实验加以证明。</p></sec><sec id="s9"><title>基金项目</title><p>遵义市特色食品和中药材创新人才团队培养项目(遵市科合[<xref ref-type="bibr" rid="hanspub.37916-ref2016">2016</xref>]7号)。</p></sec><sec id="s10"><title>文章引用</title><p>李小芬,黄旭龙,方镕泽,冯 华,王祥培. 岩陀治疗慢性支气管炎作用机制的网络药理学研究Study on the Mechanism of Treatment of Chronic Bronchitis of Rodgersia sambucifolia Hemsl. Based on Network Pharmacology[J]. 药物资讯, 2020, 09(05): 186-195. https://doi.org/10.12677/PI.2020.95028</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37916-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sethi, S. (2000) Infectious Etiology of Acute Exacerbations of Chronic Bronchitis. Chest, 117, 380.  
&lt;br&gt;https://doi.org/10.1378/chest.117.5_suppl_2.380S</mixed-citation></ref><ref id="hanspub.37916-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">程越, 邱志新, 李为民. 慢性支气管炎发病机制研究进展[J]. 华西医学, 2017, 32(4): 606-611.</mixed-citation></ref><ref id="hanspub.37916-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">高丽霓, 吕健, 王志飞, 等. 痰热清注射液治疗慢性支气管炎急性发作期的Meta分析[J]. 中国中药杂志, 2019, 10(24): 1-11.</mixed-citation></ref><ref id="hanspub.37916-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">吴明亮, 王志英, 彭丽丽, 等. 芩桑宣肃汤治疗慢性支气管炎发作期的临床观察[J]. 中国中医药科技, 2019, 26(5): 788-789.</mixed-citation></ref><ref id="hanspub.37916-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">郝宇. 小青龙汤配合针灸治疗老年慢性支气管炎的疗效观察[J]. 中国医药指南, 2019, 17(22): 185-186.</mixed-citation></ref><ref id="hanspub.37916-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">全国中草药汇编. 全国中草药汇编[M]. 第2版. 北京: 人民卫生出版社, 1996: 373.</mixed-citation></ref><ref id="hanspub.37916-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">夏从龙, 段新瑜, 何华斌, 等. 民族药岩陀药材中岩白菜素的高效液相色谱定量分析[J]. 时珍国医国药, 2009, 20(2): 289-290.</mixed-citation></ref><ref id="hanspub.37916-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">金杨, 王燕. 不同产地不同采收期岩陀药材中槲皮素的含量测定[J]. 大理学院学报, 2013, 12(9): 21-24.</mixed-citation></ref><ref id="hanspub.37916-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">王燕, 鲍家科, 金杨, 等. 岩陀药材质量标准研究[J]. 中国实验方剂学杂志, 2011, 17(10): 85-88.</mixed-citation></ref><ref id="hanspub.37916-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">陈乃江, 王统康. 高效液相色谱法测定支气管炎片中岩白菜素的含量[J]. 吉林中医药, 2008, 28(12): 918-919.</mixed-citation></ref><ref id="hanspub.37916-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">国家药典委员会. 中华人民共和国药典: 一部[M]. 北京: 中国医药科技出版社, 2015: 408.</mixed-citation></ref><ref id="hanspub.37916-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">解静, 高杉, 李琳, 等. 网络药理学在中药领域中的研究进展与应用策略[J]. 中草药, 2019, 50(10): 2257-2265.</mixed-citation></ref><ref id="hanspub.37916-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Xu, H.Y., Wang, S.S., Yang, H.J., et al. (2014) Study on Ac-tion Mechanism of Adjuvant Therapeutic Effect Compound Ejiao Slurry in Treating Cancers Based on Network Phar-macology. China Journal of Chinese Materia Medica, 39, 3148-3151.</mixed-citation></ref><ref id="hanspub.37916-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kibble, M., Saarinen, N., Tang, J., et al. (2015) Network Pharmacology Applications to Map the Unexplored Target Space and Therapeutic Potential of Natural Products. Natural Product Reports, 32, 1249-1266.  
&lt;br&gt;https://doi.org/10.1039/C5NP00005J</mixed-citation></ref><ref id="hanspub.37916-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">李飞, 赵原, 蔺瑞, 等. 中药复方药效物质及作用机制研究进展[J]. 中国药学杂志, 2019, 54(13): 1037-1044.</mixed-citation></ref><ref id="hanspub.37916-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">汝锦龙. 中药系统药理学数据库和分析平台的构建和应用[D]: [硕士学位论文]. 咸阳: 西北农林科技大学, 2015.</mixed-citation></ref><ref id="hanspub.37916-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">谢相悦, 宋春莲, 舒相华, 等. 岩陀黄酮化合物毒理性试验[J]. 中国兽医学报, 2019, 39(1): 117-120.</mixed-citation></ref><ref id="hanspub.37916-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">陈果, 王雄彪. 植物多酚类中药单体治疗哮喘研究进展[J]. 辽宁中医药大学学报, 2012, 14(4): 59-62.</mixed-citation></ref><ref id="hanspub.37916-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">任晓磊. 基于代谢组学的慢性支气管炎发病机理及岩白菜素作用机制研究[D]: [硕士学位论文]. 北京: 北京中医药大学, 2016.</mixed-citation></ref><ref id="hanspub.37916-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">红艳, 王青虎, 毕力格图, 等. 蒙药紫花高乌头总生物碱的分离鉴定及其对大鼠慢性支气管炎的治疗作用机制研究[J]. 中国药学杂志, 2019, 54(2): 91-97.</mixed-citation></ref><ref id="hanspub.37916-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">王浩, 王杰鹏, 方芳, 等. 秘精益气法对慢性支气管炎大鼠抗炎作用机制研究[J]. 时珍国医国药, 2018, 29(4): 840-842.</mixed-citation></ref><ref id="hanspub.37916-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">夏清, 潘频华, 王展, 等. 呼出气一氧化氮检测在支气管炎症性肺疾病中的临床应用[J]. 中南大学学报(医学版), 2014, 39(4): 365-370.</mixed-citation></ref><ref id="hanspub.37916-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">钱伯初, 史红, 郑晓亮. 慢性支气管炎动物模型研究进展[J]. 中国比较医学杂志, 2008(8): 53-57.</mixed-citation></ref><ref id="hanspub.37916-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Gomez, I., Foudi, N., Longrois, D., et al. (2013) The Role of Prostaglandin E2 in Human Vascular Inflammation. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA), 89, 55-63.  
&lt;br&gt;https://doi.org/10.1016/j.plefa.2013.04.004</mixed-citation></ref></ref-list></back></article>